サーファクタント関連遺伝子変異に関連する間質性肺疾患の免疫調節治療 (TIPS)
サーファクタント関連遺伝子変異に伴う間質性肺疾患の免疫調節治療
Scientific justification : Variants in surfactant-related genes (SRG) explain approximately 6% of familial pulmonary fibrosis (FPF).
The pathophysiology is unknown and seems to involve endoplasmic reticulum stress in type 2 alveolar epithelial cells.
Variable improvement in the prognosis of childhood and adult interstitial lung disease (ILD) associated with a variant of a SRG, initially reported to be lethal within months of diagnosis, has been observed since the consensual use of prednisone, azithromycin and hydroxychloroquine targeting endoplasmic reticulum stress, without demonstration of the efficacy of any of these treatments alone or in combination.
The investigators hypothesize that a treatment combining prednisone, azithromycin and hydroxychloroquine is safe and could improve the prognosis of adult patients with ILD associated with SRG variant.
Main objective and primary endpoint : Main objective:
Evaluate the efficacy of triple immunomodulatory therapy (prednisone, azithromycin and hydroxychloroquine) for 12 months in patients with ILD associated with a variant of a surfactant-related gene.
Primary endpoint:
Difference in forced vital capacity decline between the 2 groups at one year.
Secondary objectives and endpoints : Secondary objectives:
- tolerance of the triple therapy,
- correlation between the respiratory, radiological and clinical functional response,
- quality of life of the patients,
- overall survival, transplant-free survival, exacerbation free-survival, hospitalization-free survival
Secondary endpoints:
- Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (at 3, 6, 9, 12 months after randomization) (only HCQ or AZI patients) and ophthalmological (at one year after randomization)
- Thoracic CT scan and PFT at 6 months and one year after randomization
- Quality of life questionnaire (EORTC QLQ-C30, v3.0) at 3 months, 6 months, 9 months and one year after randomization,
- Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization.
Design of the study : Multicenter, randomized, controlled, two-arm, parallel, open-label superiority study comparing triple immunomodulatory therapy (prednisone, azithromycin, and hydroxychloroquine) to standard of care
Category : Category 2
Population of study participants: Patients aged over 18 years with ILD and SRG variant
Number of participants included : 30
Design of the study : Multicenter, randomized, controlled, two-arm, parallel, open-label superiority study comparing triple immunomodulatory therapy (prednisone, azithromycin, and hydroxychloroquine) to standard of care.
調査の概要
状態
条件
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Annabelle METOIS
- 電話番号:0140257939
- メール:annabelle/metois@aphp.fr
研究連絡先のバックアップ
- 名前:BORIE Raphaël
- メール:raphael.borie@aphp.fr
研究場所
-
-
-
Bron、フランス、69500
- Pneumologie Louis Pradel
-
コンタクト:
- COTTIN Vincent
- メール:vincent.cottin@chu-lyon.fr
-
Lille、フランス、59037
- Pneumologie Institu Coeur Poumon
-
コンタクト:
- WEMEAU Lidwine
- メール:lidwibne.wemeau@chru-lille.fr
-
Rennes、フランス、35033
- Pneumologie Pontchaillou
-
コンタクト:
- JOUNEAU Stéphane
- メール:stephane.jouneau@chu-rennes.fr
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age ≥ 18 years and <80 years
- Carrier of a variant classified as pathogenic or probably pathogenic or considered as eligible by the genetic multidisciplinary discussion in SFTPA1, SFTPA2, SFTPC, NKX2-1, SFTPB or two variants classified as pathogenic or probably pathogenic or considered as eligible by the genetic multidisciplinary discussion in ABCA3 or SFTPB
- ILD whatever the pattern corresponding to a volume > 10% of the total lung on a CT scan of less than 2 years
Exclusion Criteria:
- Contraindication to azithromycin and hydroxychloroquine and prednisone (details in section 6.2)
- Pregnancy and breastfeeding
- Female of childbearing potential* not willing to use reliable contraception from inclusion and during 22 months
- Desire to have a child within 22 months
- Enrolment to another interventional study (clinical trial on medicinal product, medical device and interventional research involving human participants not concerning health product)
- Subject deprived of their liberty or subject that may have insufficient power, intelligence, education, resources, strength, or other needed attributes to protect their own interests; or unable to explicitly give consent.
- No affiliation to any health insurance system
- Refusal to participate to the study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Prednisone 10 mg/day -Hydroxychloroquine 400 mg/day - Azithromycin 250mg*3
The experimental treatment will be the combination of:
|
Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no |
|
アクティブコンパレータ:Standard of care
Standard of care: any symptomatic treatment to interstitial lung disease. No other experimental or off-label treatment (such as ivacaftor) will be allowed during the study. |
Standard of care: any symptomatic treatment to interstitial lung disease. No other experimental or off-label treatment (such as ivacaftor) will be allowed during the study. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Difference in forced vital capacity decline between the 2 groups at one year.
時間枠:12 Months
|
Evaluate the efficacy of triple immunomodulatory therapy (prednisone, azithromycin and hydroxychloroquine) for 12 months in patients with ILD associated with a variant of a surfactant-related gene. |
12 Months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
tolerance of the triple therapy
時間枠:12 months
|
Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (including QTc prolongation) (at 3, 6, 9, 12 months after randomization) (only HCQ or AZI patients) and ophthalmological (at 6 months and 12 months after randomization) |
12 months
|
|
correlation between the respiratory, radiological and clinical functional response,
時間枠:12 months
|
Thoracic CT scan (progression criteria [99]) and PFT (Pulmonary function tests) at one year after randomization |
12 months
|
|
Quality of life of the patients
時間枠:12 months
|
Quality of life questionnaire (SF-36, scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 : a validated patient-reported questionnaire for assessing quality of life in cancer patients.) at one year after randomization, |
12 months
|
|
tolerance of the triple therapy
時間枠:6 months
|
Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (including QTc prolongation) at 6, months after randomization (only HCQ or AZI patients) and ophthalmological (at one year after randomization) |
6 months
|
|
tolerance of the triple therapy
時間枠:3 months
|
Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (including QTc prolongation) at 3 months after randomization (only HCQ or AZI patients) and ophthalmological (at one year after randomization) |
3 months
|
|
correlation between the respiratory, radiological and clinical functional response,
時間枠:6 months
|
Thoracic CT scan (progression criteria [99]) and PFT (Pulmonary function tests) at 6 months after randomization |
6 months
|
|
Quality of life of the patients
時間枠:9 months
|
Quality of life questionnaire (SF-36,scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 : a validated patient-reported questionnaire for assessing quality of life in cancer patients.) at 9 months after randomization, |
9 months
|
|
Quality of life of the patients
時間枠:6 months
|
Quality of life questionnaire (SF-36 scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 :a validated patient-reported questionnaire for assessing quality of life in cancer patients. ) at 6 months after randomization, |
6 months
|
|
Quality of life of the patients
時間枠:3 months
|
Quality of life questionnaire (SF-36, scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 :a validated patient-reported questionnaire for assessing quality of life in cancer patients ) at 3 months after randomization, |
3 months
|
|
Overall survival
時間枠:12 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization |
12 months
|
|
Transplant-free survival
時間枠:12 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization |
12 months
|
|
Exacerbation free-survival
時間枠:12 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization |
12 months
|
|
Hospitalization-free survival
時間枠:12 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization |
12 months
|
|
tolerance of the triple therapy
時間枠:9 months
|
Clinical and biological tolerance (occurrence of an adverse effect during treatment), |
9 months
|
|
tolerance of the triple therapy
時間枠:12 months
|
ECG (including QTc prolongation) at 12 months after randomization (only HCQ or AZI patients) |
12 months
|
|
tolerance of the triple therapy
時間枠:12 months
|
Ophthalmological (at one year after randomization) |
12 months
|
|
tolerance of the triple therapy
時間枠:9 months
|
ECG (including QTc prolongation) at , 9 months after randomization (only HCQ or AZI patients) |
9 months
|
|
tolerance of the triple therapy
時間枠:6 months
|
ECG (including QTc prolongation) at 6 months after randomization (only HCQ or AZI patients) |
6 months
|
|
tolerance of the triple therapy
時間枠:3 months
|
ECG (including QTc prolongation) at 3 months after randomization (only HCQ or AZI patients) |
3 months
|
|
Overall survival
時間枠:9 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 9 months after randomization |
9 months
|
|
Overall survival
時間枠:6 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 6 months after randomization |
6 months
|
|
Overall survival
時間枠:3 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 3 months after randomization |
3 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。